Industry | 制造业 | ||||||||||||||||||||||||
Company Introduction | 公司是一家主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业,专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发,并围绕上述治疗领域拥有一定中药及化学药技术沉淀。目前公司主要产品包括重组蛋白药物“重组人促红素”、“重组人干扰素α1b”、“重组人粒细胞刺激因子”,微生态制剂药物“酪酸梭菌二联活菌”。 公司主要产品已沉淀一定行业优势地位和市场影响力,近年来依托政策支持和营销渠道深耕,保持稳定增长。同时,公司经过二十几年的医药研发与产业化技术沉淀,已构建较为完整的药物研发创新体系,覆盖从药物发现、药学研究、临床前研究、临床研究至产业化的医药创新能力。公司技术中心2017年被认定为“山东省省级企业技术中心”,2018年被认定为“济南市蛋白药物工程实验室”,2020年被认定为“广东省基因工程重组蛋白药物工程技术中心”、“山东省蛋白质药物工程实验室”。公司拥有一支高素质、高学历、行业经验丰富的研发队伍,截至2020年6月30日,公司研发人员共169人,截至本招股意向书签署日,公司拥有各类专利36项,其中发明专利24项。 公司以创新为驱动力,已储备梯队化、系列化、递进式的生物药在研项目,截至本招股意向书签署日,公司在研生物药项目8项。公司根据医药市场环境调研发战略,2019年第四季度以来逐步缩减化学药研发投入,着力聚焦具有优势技术沉淀的生物药主航道,并采用深耕优势技术和拓展前沿生物技术相结合的产品战略,按照“近期—中期—远期”的阶段规划产品线,后续将持续加大生物药研发创新投入力度。 | ||||||||||||||||||||||||
Main Business | 主要从事重组蛋白药物和微生态制剂的研发、生产、销售一体化的创新型生物制药企业,专注于抗病毒、血液、肿瘤与免疫、退行性疾病等治疗领域的药物研发,并围绕上述治疗领域拥有一定中药及化学药技术沉淀。 | ||||||||||||||||||||||||
Legal Representative | 邓学勤 | ||||||||||||||||||||||||
Top Executives |
|
||||||||||||||||||||||||
Top 5 Shareholder |
|
||||||||||||||||||||||||
Company Secretary | 王小琴 | ||||||||||||||||||||||||
Solicitors | 北京市嘉源律师事务所 | ||||||||||||||||||||||||
Auditors | 大华会计师事务所(特殊普通合伙) | ||||||||||||||||||||||||
Tel No | 0755-86967773 | ||||||||||||||||||||||||
Fax No | 0755-86967891 | ||||||||||||||||||||||||
Website | www.kexing.com | ||||||||||||||||||||||||
ir@kexing.com | |||||||||||||||||||||||||
Company Address |
|
||||||||||||||||||||||||
Listing Date | 14/12/2020 | ||||||||||||||||||||||||
Shares Capital |
|
||||||||||||||||||||||||
EPS(RMB)* | ¥ -0.960 | ||||||||||||||||||||||||
DPS(RMB)* | -- | ||||||||||||||||||||||||
NBV Per Share(RMB)* | ¥ 8.163 | ||||||||||||||||||||||||
Market Capitalization(RMB) | 3.604B |
Only Chinese content is avaliable | |
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
* | Unadjusted Data |
Information provided by: etnet | ||
Terms and Conditions |
Risk Disclosure: |
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
Disclaimer: |
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |